Identification of non-invasive biomarkers for early detection of breast cancer: A Review

2021 ◽  
Vol 2 (1) ◽  
pp. 01-05
Author(s):  
Asima Tayyab
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Potential Role ◽  
Small Volume ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Purpose ◽  
Diagnose Breast Cancer ◽  
Non Invasive ◽  
Early Stages

Despite decades of research, diagnostic tests with specificity and accuracy for early breast cancer are yet unavailable. Major problems associated with poor diagnosis are either due to incompetency of reported biomarkers or small volume of patients under study. Moreover, heterogeneity of the disease further complicates the struggle of identifying effective biomarkers. Therefore, to improve the survival rate, look for new, sensitive and specific biomarkers for early breast cancer diagnosis is need of hour. In this study, we have reviewed recently reported serum biomarkers and categorized them based on their biomolecular nature such as protein, ctDNA, epigenetics regulation and miRNA. Potential role of these available biomarkers in early diagnosis of breast cancer has also been discussed. Based on the facts obtained from literature review, it is revealed that using any individual biomolecule as a biomarker is not sufficient to diagnose breast cancer at early stages rather it is suggested that a panel of proteins or miRNAs would offer better sensitivity and specificity. Whereas, unavailability of a potential ctDNA and epigenetics regulation candidate for diagnostic purpose is and suggest the use of more sophisticated techniques to unwound these regulations in serum especially at early stages of breast cancer.

scholarly journals Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes

2020 ◽  
Vol 10 (3) ◽  
pp. 98
Author(s):  
Veronica Zelli ◽  
Chiara Compagnoni ◽  
Roberta Capelli ◽  
Katia Cannita ◽  
Tina Sidoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Potential Role ◽  
Molecular Subtypes ◽  
Therapeutic Strategies ◽  
Circulating Mirnas ◽  
Circulating Micrornas ◽  
Non Invasive ◽  
Biological Features ◽  
Non Coding Rna

Breast cancer (BC) is a common and heterogeneous disease, of which six molecular subtypes, characterized by different biological features and clinical outcomes, were described. The identification of additional biomarkers able to further connote and distinguish the different BC subtypes is essential to improve the diagnostic, prognostic and therapeutic strategies in BC patients. MicroRNAs (miRNAs) are short non-coding RNA involved in several physiological and pathological processes, including cancer development and progression. In particular, circulating miRNAs, which can be found in an adequately stable structure in serum/plasma of cancer patients, are emerging as very promising non-invasive biomarkers. Several studies have analyzed the potential role of circulating miRNAs as prognostic and therapeutic markers in BC. In the present review we describe circulating miRNAs, identified as putative biomarker in BC, with special reference to different BC molecular subtypes.

MicroRNAs as Biomarker for Breast Cancer

2020 ◽  
Vol 20 (10) ◽  
pp. 1597-1610 ◽  
Author(s):  
Taru Aggarwal ◽  
Ridhima Wadhwa ◽  
Riya Gupta ◽  
Keshav Raj Paudel ◽  
Trudi Collet ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Association Studies ◽  
Large Family ◽  
Breast Cancer Diagnosis ◽  
Cell Multiplication ◽  
Cell Physiology ◽  
Gene Transcript ◽  
Genome Wide Association Studies ◽  
Non Coding Rnas

Regardless of advances in detection and treatment, breast cancer affects about 1.5 million women all over the world. Since the last decade, genome-wide association studies (GWAS) have been extensively conducted for breast cancer to define the role of miRNA as a tool for diagnosis, prognosis and therapeutics. MicroRNAs are small, non-coding RNAs that are associated with the regulation of key cellular processes such as cell multiplication, differentiation, and death. They cause a disturbance in the cell physiology by interfering directly with the translation and stability of a targeted gene transcript. MicroRNAs (miRNAs) constitute a large family of non-coding RNAs, which regulate target gene expression and protein levels that affect several human diseases and are suggested as the novel markers or therapeutic targets, including breast cancer. MicroRNA (miRNA) alterations are not only associated with metastasis, tumor genesis but also used as biomarkers for breast cancer diagnosis or prognosis. These are explained in detail in the following review. This review will also provide an impetus to study the role of microRNAs in breast cancer.

scholarly journals Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer

ESMO Open ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 100076
Author(s):  
A. Matikas ◽  
K. Wang ◽  
E. Lagoudaki ◽  
B. Acs ◽  
I. Zerdes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Thymidine Kinase ◽  
Early Breast Cancer ◽  
Prognostic Role ◽  
Thymidine Kinase 1 ◽  
Serum Thymidine Kinase 1

scholarly journals Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review

2020 ◽  
Vol 21 (16) ◽  
pp. 5834
Author(s):  
Anna Maria Grimaldi ◽  
Silvia Nuzzo ◽  
Gerolama Condorelli ◽  
Marco Salvatore ◽  
Mariarosaria Incoronato
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Prognostic Biomarker ◽  
Survival Rates ◽  
Prognostic Significance ◽  
Unmet Need ◽  
Non Invasive ◽  
Clinicopathological Significance ◽  
Present Systematic Review

There is an unmet need for novel non-invasive prognostic molecular tumour markers for breast cancer (BC). Accumulating evidence shows that miR-155 plays a pivotal role in tumorigenesis. Generally, miR-155 is considered an oncogenic miRNA promoting tumour growth, angiogenesis and aggressiveness of BC. Therefore, many researchers have focused on its use as a prognostic biomarker and therapeutic target. However, its prognostic value for BC patients remains controversial. To address this issue, the present systematic review aims to summarize the available evidence and give a picture of a prognostic significance of miR-155 in BC pathology. All eligible studies were searched on PubMed and EMBASE databases through various search strategies. Starting from 289 potential eligible records, data were examined from 28 studies, comparing tissue and circulating miR-155 expression levels with clinicopathological features and survival rates in BC patients. We discuss the pitfalls and challenges that need to be assessed to understand the power of miR-155 to respond to real clinical needs, highlighting the consistency, robustness or lack of results obtained to sate in translating this molecule to clinical practice. Our paper suggests that the prognostic role of miR-155 in the management of BC needs to be further verified.

Sign in / Sign up

Export Citation Format

Share Document